Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.
Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.
MedPage Today on MSN
Parkinson's disease gets new treatment approved
FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...
The actor was diagnosed eight years ago, according to his caretaker.
Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...
Brought into the limelight by actor Michael J. Fox, Parkinson's disease affects the body's ability to control movement. The most prominent signs of Parkinson's disease result from damage to brain ...
The actor's ex-wife, Sarah Quinones, told TMZ on Tuesday that Haskins was in an assisted living facility at the end of his life.
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
This Perspective outlines the challenges addressed at the first Annual Parkinson’s Disease (PD) Prevention Think Tank, held on November 20–21, 2025 in Gainesville, Florida at ...
Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.
Share on Pinterest How might groundwater impact Parkinson’s disease risk? New research investigates. Image credit: Catherine Falls Commercial/Getty Images A recent study evaluated how groundwater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results